Cytomegalovirus (CMV) DNAemia was detected by PCR in 30/125 (24%) consecutive paediatric patients undergoing allogeneic stem cell transplantation. All patients with CMV DNAemia received pre-emptive ganciclovir until two consecutive negative results were obtained. CMV-IgG-positive patients (R+) had a significantly increased risk of DNAemia as compared to CMV-IgGnegative (RÀ) patients (62% vs 8%) Po0.0001. The incidence of DNAemia was 71% (10/14) in R+ transplanted from seronegative donors (DÀ) compared to 54% (13/32) in those transplanted from seropositive donors (D+). Of 30 (40%) children with DNAemia, 12 developed CMV disease despite pre-emptive treatment. The overall incidence of disease was 0% (0/59) for RÀ/ DÀ, 9% (3/23) for R+/D+, 7% (2/29) for RÀ/D+ and 57% (8/14) for R+/DÀ. In patients with DNAemia, 4/20 (20%) patients with D+ and 8/10 (80%) with DÀ became symptomatic. In the multivariate analysis of both groups, patients at risk (R+ and/or D+) and patients with DNAemia, a negative donor serostatus was the only factor associated with a significantly increased incidence of disease. Seven of 9 patients with lethal CMV disease had received CMV-IgG-negative grafts. The data suggest that in CMV seropositive recipients donor CMV seropositivity is associated with a reduced incidence of CMV disease and a favourable outcome following pre-emptive treatment.
Introduction
CMV infection is known to have an important impact on morbidity and transplant-related mortality (TRM) following allogeneic stem cell transplantation (SCT) in adults 1, 2 CMV DNAemia can be detected by pp65-antigenaemia or polymerase chain reaction (PCR) before the onset of CMV disease in many cases. Recipient and/or donor CMV seropositivity, SCT from unrelated donors, T-cell depletion and graft-versus-host disease (GvHD) are risk factors for CMV infection and CMV disease. [3] [4] [5] CMV disease following SCT, particularly pneumonitis, is lethal in most instances. 5, 6 Recently, different authors described the impact of recipient CMV-seropositivity on TRM. [7] [8] [9] The reported overall actuarial risk of CMV DNAemia during paediatric SCT varies between 30% and 50%. 10, 11 Pre-emptive treatment with ganciclovir or foscarnet has become a widely accepted therapeutic option. 12 By PCRbased pre-emptive treatment early-onset CMV disease can be reduced, but some patients need prolonged therapy and recurrence may be a problem. The duration of antiviral therapy prior to day +100 has been described as a significant risk factor for late-onset CMV disease. 13 In seropositive adults receiving T-cell-depleted grafts from seronegative donors, more treatment failures have been described. 14 In the current study, we have assessed the impact of recipient and donor CMV serostatus on CMV DNAemia, CMV disease and CMV-associated mortality in paediatric SCT patients receiving pre-emptive therapy for CMV DNAemia.
Patients and methods
Between February 1995 and March 2001, 129 paediatric patients underwent allogeneic SCT in the St Anna Children's Hospital, Vienna, Austria. Recipient and donor characteristics, source of stem cells and GvHD prophylaxis are summarized in Table 1 . Patients with severe aplastic anaemia, patients with matched unrelated or HLA-non identical donors and those with T-cell-depleted grafts received ATG as part of the conditioning regimen.
Additional ex-vivo T-cell depletion by CD34+ positive selection was performed in 45 cases: 21 patients with haploidentical family donors and 24 patients with nonmalignant diseases who received peripheral blood stem cells from unrelated donors. The median T-cell count in the Tcell-depleted grafts was 0.5 Â 10 4 CD3+ cells/kg. GvHD prophylaxis consisted of cyclosporin and -in patients with unrelated donors -short-course MTX. Antiviral prophylaxis included acyclovir (30 mg/kg/day i.v.) between days À7 and +28, and immunoglobulin substitution every other week. Seronegative patients received platelets from CMVseronegative donors, and blood products were leukocyte depleted by filtration.
Four patients who had CMV disease before transplantation were excluded from the evaluation. Patients were screened by PCR for CMV twice weekly, from day À7 until day +40, and every other week until day +100. In CMV-PCR-positive patients, screening was continued on a weekly basis from day +40 until two subsequent negative results were obtained. CMV-specific DNA sequences were analysed in EDTA blood using single-step PCR. Primers amplifying a region of the major immediate early gene were used. 15 The sensitivity of the CMV-PCR was 10 In case of DNAemia, primary pre-emptive treatment was started with ganciclovir; if viral load did not decrease within 2 weeks, secondary pre-emptive treatment consisted of foscarnet or cidofovir. 17 Pre-emptive treatment was continued until at least two negative CMV-PCR results were obtained.
CMV disease was defined by clinical symptoms (pneumonia, enteritis, hepatitis), together with detection of CMV in bronchoalveolar lavage, gut or liver biopsy by culture, histopathology, PCR and/or in situ hybridization.
T-cell engraftment was monitored in 85 patients by flow cytometric analysis twice weekly until day +28. Delayed Tcell engraftment was defined as less than 100 CD3+ cells/ml on day +28. Median observation time was 46.2 months (range 6.1-79.6). TRM was defined by death because of transplant related events until day +365.
Multiple logistic regression analysis was performed with dependent variable DNAemia and disease, respectively. The influence factors were the patient's serostatus, the donor's serostatus, or the combination of the patient's and the donor's serostatus, the manipulation of the graft, the donor type and the degree of GvHD. Cox's proportionalhazard model was used to asses the influence of these factors on time till transplant-associated mortality. Kaplan-Meier estimates of survival were calculated and the groups compared using the log-rank test.
Results

CMV DNAemia
The incidence of CMV DNAemia between day À7 and + 100 was 24% in the whole cohort and 44% in patients at risk (ie CMV seropositivity of recipient and/or donor). The median time point of the first positive result was day +12 (range À1 to +65). Patients transplanted from matched sibling donors had the lowest incidence of DNAemia 11% (4/37) compared to those with matched unrelated donors 28% (19/67) and haploidentical family donors 33% (7/21); however, the difference was not statistically significant. Patients who received unmanipulated grafts without ATGcontaining conditioning regimens had a reduced incidence of DNAemia compared to patients with in vivo +/À ex vivo T-cell depletion: 11 vs 30%. Delayed T-cell engraftment was not correlated with a significantly higher incidence of DNAemia: 31% of the patients with o100 CD3+ T cells/ ml blood on day +28, and 20%) of those with a CD3+ Tcell count 4100/ml cells/ml on day +28 became CMV-PCR positive. Two patients were not evaluable for GvHD. There was no correlation between DNAemia and the overall incidence of acute GvHD: 23% (16/70) of patients with acute GvHD vs 24% (13/53) without acute GvHD became PCR positive. However, 15/94 (16%) patients without DNAemia developed grades III-IV GvHD compared to Impact of donor CMV-serology on CMV disease in SCT patients S Matthes-Martin et al 12/30 (40%) patients with DNAemia and grades III-IV GvHD were associated with a significantly higher incidence of DNAemia compared to patients with grades 0-II GvHD: 44% (12/27) vs 25% (17/68) (Wald's w 2 test Pvalue 0.003). The relations between CMV infection and donor type, T-cell depletion and GvHD are shown in Table 2 .
CMV-IgG-positive patients (R+) had a significantly higher incidence of DNAemia compared to CMV-IgGnegative patients (RÀ): 62% (23/37) vs 8% (7/88) (Walds w 2 test, P-value o0.0001). The incidence of DNAemia was 2% for RÀ/DÀ, 21% for RÀ/D+, 57% for R+/D+ and 71% for R+/DÀ, respectively. As the univariate analysis suggested significant influence of the patient's serostatus, the donor's serostatus, and the degree of GvHD, these variables were chosen as possible influence factors in the multivariate logistic regression analysis. Severe GvHD and positive recipient as well as donor serostatus turned out to stay significantly influential on DNAemia. The odds ratio estimates, the bounds for 95% confidence intervals and the P-values (Walds w 2 test) of the multivariate logistic regression model are given in Table 3 .
The duration of antiviral treatment was longer in patients transplanted from seronegative donors (median 8 weeks) compared to those transplanted from seropositive donors (median 4 weeks). In 14/27 (51%) cases successful pre-emptive treatment was followed by late recurrence of DNAemia. A second course of pre-emptive treatment was effective in five of the 14 patients.
CMV disease
Of 30(40%) patients with DNAemia, 12 developed CMV disease between days +6 and +126 (median +78) despite pre-emptive treatment. Only three patients became symptomatic during primary DNAemia. By contrast, 9/14 (64%) patients who experienced late recurrence following successful primary pre-emptive treatment became symptomatic during the second course of pre-emptive treatment. The median interval between recurrence of viraemia (and thus reinduction of pre-emptive treatment) and disease was 4.5 weeks (range 2-8.5). Nine patients developed pneumonia, associated with hepatitis in one case. In 7/9 patients with pneumonia diagnosis was confirmed by histopathology and/or in situ hybridization, two patients with interstitial pneumonitis were CMV-PCR positive in bronchoalveolar lavage and pleural effusion in the absence of other pathogens. Two children had enteritis: in one patient gut biopsy revealed CMV-positive histopathology, one patient with increasing CMV DNAemia, and prolonged enteritis in the absence of GvHD and repeatedly CMV-positive stool probes was stated as CMV enteritis without gut biopsy. One patient developed isolated hepatitis, liver biopsy was CMV-PCR positive; however, histopathology was not conclusive.
There was no significant difference in the incidence of disease between recipients of MSD (8%), MUD (9%) and haploidentical donors (5%). Ex vivo and/or in vivo T-cell depletion and delayed T-cell engraftment had no significant impact on the incidence of CMV disease. In all, 6/71 (8.7%) patients with severe GvHD (and consequently additional immunosuppressive therapy with steroids +/À IL-2-receptor antibody) became symptomatic, compared to 6/54 (11%) patients without any additional immunosuppression.
As expected, overall, R+ was associated with a significantly higher incidence of disease compared to RÀ, 27% vs 2% (Walds w 2 test, P-value o0.0001). Regarding the seronegative patients, the incidence of disease was 7% in RÀ/D+ and none of the seronegative recipients of seronegative donors became symptomatic. In the seropositive cohort, the incidence of disease was 9% (2/23) for R+/D+in contrast to 57% (8/14) for R+/DÀ. To calculate the risk factors for CMV disease, seronegative patients with seronegative donors were excluded from the multivariate analysis. The combination of the patient's and the donor's serostatus, in vivo+/Àex vivo T-cell depletion, the degree of GvHD (grades 0 vs III-IV) and the donor type were considered possible risk factors. Only the combination of the patient's and donor's serostatus showed significant influence on the development of CMV disease. Odds ratio estimates, bounds for the 95% confidence intervals and the P-values for the combinations of recipient and donor serostatus are given in Table 4 .
The incidence of progression from DNAemia to CMV disease despite pre-emptive treatment was 73% (8/11) in patients with seronegative donors vs 21% (4/19) in patients with seropositive donors. For patients with DNAemia Data on T-cell engraftment at the onset of CMV disease were available in seven patients: 5/7 patients had a CD3+counto100/ml, both patients with higher T-cell counts (41000/ml) had been transplanted from DÀ.
CMV-and transplant-related mortality
Despite intensive treatment, CMV disease was lethal in 9/12 cases. Seven of nine patients who died in the course of their CMV disease had received a CMV-seronegative graft.
Incidence of CMV DNAemia, CMV disease and TRM in relation to patient and donor CMV serostatus is shown in Figure 1 . The overall TRM was 30%: patients who had experienced CMV DNAemia during the course of SCT had a significantly higher incidence of TRM compared to patients without CMV reactivation 60% (18/30) vs 21% (20/95), (Walds w 2 test P-valueo0.0001). However, TRM in patients with DNAemia was higher in patients who had received a seronegative graft: 9/11 (81%) of patients with DNAemia and seronegative donors compared to 9/19 (47 %) of those with seropositive donors died transplant associated (Figure 2 ).
Discussion
In all, 24% of our paediatric patients who underwent allogeneic SCT developed CMV DNAemia. As expected, patients with unmanipulated grafts had a decreased incidence of DNAemia. Surprisingly, additional ex vivo T-cell depletion and delayed T-cell engraftment did not correlate with an increased incidence of viraemia. 6, 18 In contrast to other published data, we found a higher incidence of viraemia in patients transplanted from alternative donors as compared to those transplanted from matched sibling donors, but this difference was not significant and might be because of the fact that in our patient cohort with sibling donors, 54% of the recipientdonor pairs were CMV-IgG negative. 19, 20 The median time point of the first CMV-PCR-positive result was day +12. One explanation for the detection of DNAemia within the first 2 weeks following SCT in most cases might be the paediatric patient cohort: pre-existing immunosuppression by underlying disease or prolonged intensive chemotherapy prior to transplant together with a highly immunosuppressive conditioning regimen (74% of the patients received ATG in the course of their conditioning).
In univariate as well as in multivariate analysis GvHD grades II-IV and a positive patient serostatus were associated with a significantly increased risk of DNAemia, despite the fact that significantly more patients with DNAemia had received a T-cell-depleted graft (and should therefore have a substantially reduced risk for GvHD).
These findings and the fact that DNAemia frequently is present prior to engraftment and GvHD give rise to the notion that CMV infection might trigger GvHD.
There have been various attempts to assess the role of target organ infection in the pathogenesis of GvHD, and CMV might enhance the immune system reactivity or alter the host tissue antigenicity. 21 Data on organ transplanta- -----) ).
Impact of donor CMV-serology on CMV disease in SCT patients S Matthes-Martin et al tion concerning CMV infection and the mechanism of organ rejection might support this hypothesis. 22, 23 Furthermore, recipient CMV seropositivity is known to be a risk factor for severe GvHD. 7, 24 As reported in other studies, recipient seropositivity had a significant impact on the incidence of CMV viraemia and disease. 4, 14 Together with the observation of Couriel et al, 6 who did not find an increased risk of CMV DNAemia following transfusion of lymphocytes from CMV-seropositive donors, these data suggest that reactivation of latent virus in the host is the most frequent cause of DNAemia. In our study, CMV-PCR-positive patients had a significantly reduced incidence of disease if the donor was seropositive.
Ljungman et al 25 reported that patients who developed CMV pneumonia had no measurable specific helper T-cell response at the time of viraemia detection, and Reusser et al 26 observed that none of the patients with CMVspecific CTL responses developed pneumonia. Gor et al 27 found a significantly higher viral load in seropositive recipients of seronegative marrow in the absence of preemptive treatment, suggesting that the peripheral expansion of CMV-specific T-cell clones within the first months after SCT depends on the donor serostatus. The study published by Nichols et al 28 revealed a significant impact of donor CMV serostatus on rising antigenaemia during pre-emptive treatment in univariate but not in multivariate analysis. 28 However, this might be because of the fact that only 5/119 donors had been CMV-IgG negative. Recently, Gratama et al 14 reported a higher incidence of CMV antigenaemia and disease after SCT from CMV-seronegative donors and a prolonged need for pre-emptive treatment in adults. In our study, 73% of the CMV-PCR-positive patients with a seronegative donor, but only 21% of those with a seropositive donor became symptomatic, and 7/9 patients with lethal CMV disease had received a seronegative graft, suggesting that the success of anti-CMV therapy highly depends on the donor serostatus. CMV DNAemia after allogeneic BMT is known to be associated with increased TRM. 2 The use of CMV-PCR-guided pre-emptive treatment with ganciclovir seems to reduce TRM in transplanted patients.
1, 29 Locatelli et al 10 did not observe a significant difference in TRM between patients with and without DNAemia using a pre-emptive treatment protocol. In our study, TRM was lower in patients with DNAemia and seropositive donors compared to those with seronegative donors (47 vs 81%). An EBMT megafile analysis performed by Ljungman et al 30 found a significantly reduced TRM in patients with CML receiving unrelated transplants from CMV-IgG-positive donors.
We conclude that the donor CMV serostatus has a significant impact on the incidence of CMV DNAemia in patients at risk and the outcome following pre-emptive treatment in paediatric patients with DNAemia.
